Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S stock logo
GMAB
Genmab A/S
$19.40
+0.5%
$19.90
$17.24
$30.41
$12.43B1.041.10 million shs311,571 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.74
$64.09
$131.98
$14.05B0.691.49 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$24.88
-2.4%
$28.52
$23.15
$170.47
$9.63B1.997.61 million shs1.74 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$46.25
-0.3%
$48.62
$28.72
$58.38
$3.67B0.52853,167 shs53,601 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S stock logo
GMAB
Genmab A/S
-3.11%-5.44%+2.66%-1.93%-33.78%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%+3.05%+98.84%
Moderna, Inc. stock logo
MRNA
Moderna
-0.82%+4.49%-2.71%-16.51%-79.72%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
+0.83%+28.18%+7.93%-5.19%+46.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S stock logo
GMAB
Genmab A/S
4.1538 of 5 stars
4.33.00.00.03.30.03.1
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.6939 of 5 stars
1.10.00.04.50.61.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.4688 of 5 stars
4.01.00.04.62.72.51.3
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.2563 of 5 stars
4.33.00.04.42.50.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S stock logo
GMAB
Genmab A/S
2.69
Moderate Buy$39.17101.92% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$53.95116.83% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$61.9233.88% Upside

Current Analyst Ratings Breakdown

Latest PTCT, GMAB, ITCI, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $68.00
5/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.00
5/7/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$50.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$50.00 ➝ $32.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S stock logo
GMAB
Genmab A/S
$21.64B0.57$1.31 per share14.80$8.04 per share2.41
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.07N/AN/A$28.33 per share0.88
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$1.77B2.07$2.22 per share20.80($10.85) per share-4.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7611.1410.902.6536.30%16.78%13.79%N/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-110.04%-28.74%-21.83%N/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$626.60M$6.51N/AN/AN/A-50.32%N/A-16.44%N/A

Latest PTCT, GMAB, ITCI, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Genmab A/S stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
2/21/2025Q4 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
2.10
2.04

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
1,660641.20 million651.58 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.74 million324.40 millionOptionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million72.88 millionOptionable

Recent News About These Companies

PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Buy" at Bank of America
Cantor Fitzgerald Issues Positive Estimate for PTCT Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$19.40 +0.09 (+0.45%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$24.88 -0.61 (-2.39%)
As of 10:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$46.25 -0.14 (-0.30%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.